GA recommends early use of biologics in patients with moderate-to-severe Crohn’s disease

Written by | 3 Jun 2021 | Endocrine System

Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations and surgery when not adequately controlled. While there is no cure for Crohn’s disease, there are treatments that can help patients live a symptom-free life.

After a detailed review of available literature, the American Gastroenterological Association (AGA) has released new clinical guidelines outlining the benefits and risks of each drug currently available to Crohn’s patients. Based on this research, AGA recommends the early introduction of biologics for patients experiencing luminal and fistulizing Crohn’s disease rather than waiting until other treatments fail. These guidelines are published in Gastroenterology, AGA’s official journal.

“With many new drugs entering the market, clinician’s ability to treat patients with Crohn’s disease has improved greatly over the last 20 years,” said lead author Joseph D. Feuerstein, MD, from Beth Israel Deaconess, Boston, Massachusetts. “We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery.”

Key guideline recommendations:

  1. Biologics are the most effective drugs for the management of Crohn’s and they should be used early, rather than delaying their use until after failure of mesalamine and/or corticosteroids, in patients with moderate to severe or fistulizing Crohn’s disease. These drugs are antibodies and can more precisely target the immune system which is causing the inflammation in Crohn’s disease.
  2. Anti-tumor necrosis factor (anti-TNF) agents or ustekinumab are recommended and vedolizumab is suggested as a first-line treatment.
  3. In patients who have previously not responded to anti-TNF agents, AGA recommends ustekinumab or vedolizumab.
  4. The biologic natalizumab is no longer recommended due to potential adverse events and the availability of safer treatment options.

Journal Reference:

  1. Joseph D. Feuerstein, Edith Y. Ho, Eugenia Shmidt, Harminder Singh, Yngve Falck-Ytter, Shanaz Sultan, Jonathan P. Terdiman, Shahnaz Sultan, Benjamin L. Cohen, Karen Chachu, Lukejohn Day, Perica Davitkov, Benjamin Lebwohl, Theodore R. Levin, Amit Patel, Anne F. Peery, Raj Shah, Harminder Singh, Siddharth Singh, Stuart J. Spechler, Kyle Staller, Aaron P. Thrift, Jennifer M. Weiss. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s DiseaseGastroenterology, 2021; 160 (7): 2496 DOI: 1053/j.gastro.2021.04.022
Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.